| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Monday, May 13, 2019 In what could be "the largest cartel case in the history of the United States," 44 states sued 20 generics makers Friday for price fixing and personally named 15 of those companies' executives. And at the center of the scheme, the lawsuit claims, was Teva. |
|
|
| This week's sponsor is FierceBiotech. | | | |
Top Stories Of The Week Wednesday, May 15, 2019 Private biotechs raised a record-breaking $16.8 billion in 2018, blowing past the record $12.1 billion set the previous year. Here are the top 10 fundraising rounds—which broke some records themselves—and together illustrate what's hot out there in the field. Monday, May 13, 2019 ElevateBio seeks to address a bottleneck faced by cell and gene therapy developers: manufacturing. With $150 million in series A funding, the holding company will provide centralized R&D and manufacturing teams to its portfolio companies. Friday, May 10, 2019 Medtronic is walking away from the knee replacement work being done by Responsive Orthopedics, a startup it acquired in 2016 that had aimed to disrupt the market with lower-cost artificial joints and a bundled payment model, and making new inroads within its spine implant business with the acquisition of Titan Spine. Tuesday, May 14, 2019 Boehringer Ingelheim fought hard against AbbVie’s so-called patent thicket surrounding the world’s bestselling drug, Humira. But in the end, the German company ended up settling on a 2023 launch date, just like its fellow biosimilar makers. Wednesday, May 15, 2019 After HHS proposed eliminating drug rebates in Medicare and Medicaid, pharma cheered. But now, two officials from both major political parties have come up with a possible alternative, according to a BioCentury report. Tuesday, May 14, 2019 Daiichi Sankyo went one for two in an FDA cancer advisory committee doubleheader Tuesday, with its prospective leukemia treatment getting struck out. Wednesday, May 15, 2019 The FDA has quashed ImmunoGen’s hopes of filing for approval of mirvetuximab soravtansine on the strength of a failed phase 3. FDA officials advised ImmunoGen a run a new phase 3 in patients with high folate receptor alpha-positive, platinum-resistant ovarian cancer before seeking approval. Wednesday, May 15, 2019 Pfizer’s FDA-approved JAK inhibitor Xeljanz is currently struggling with cardiovascular safety concerns. But another candidate in the family for which Pfizer has blockbuster hopes just slew a phase 3 in atopic dermatitis, teeing up a fight against Sanofi and Regeneron’s Dupixent. Friday, May 10, 2019 Semma Therapeutics has faced an obstacle with its process of turning undifferentiated pluripotent stem cells into insulin-producing pancreatic beta cells: Only 30% of the resulting cells turn out to be beta cells. Now, a Semma-Harvard University team has figured out how to boost the proportion of beta cells emerging from their process to 80%. Monday, May 13, 2019 A year after Torrent Pharmaceuticals first began recalling tainted losartan products manufactured at its Indrad plant, the FDA paid a visit. It found a plant that often routinely reported products out of specification but frequently shipped them to the U.S. anyway. Resources Sponsored by: Catalent Download the executive summary to learn key considerations for a successful technology transfer for manufacturing drug products, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Patheon, part of Thermo Fisher Scientific Choosing the Best Sterile Dosage Form for Your Phase I Clinical Supply Needs. Sponsored by: Patheon, part of Thermo Fisher Scientific Designed with speed & flexibility,Quick to Clinic™ for Oral Solid Dose helps deliver products to Phase I Clinic in as little as 14 weeks. Sponsored by: AlphaSense What is agile competitive intelligence, and how can help healthcare researchers stay ahead of the curve? Presented by: Total Brain Total Brain Announces Personalized Test for Treatment Prediction in Depression with 80% Accuracy. Sponsored by: Veradigm Prescription price transparency technology is here – but is it making a difference? Find out HERE. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. |
